LUTS & Cancer pathway. Mr Francis Thomas Urology Consultant DRI &BDGH

Similar documents
Lower Urinary Tract Symptoms K Kuruvilla Zachariah Associate Specialist

Policy for Prostatism/Lower Urinary Tract Symptoms in men

Case studies: LUTS. Case 1 history. Case 1 - questions. Case 1 - outcome. Case 2 - history. Case 1 learning point 14/07/2015 DR JON REES

Clinical guideline Published: 23 May 2010 nice.org.uk/guidance/cg97

Overactive Bladder Syndrome

BPH / LUTS. Prevalence. Prevalence of BPH. It is abnormal NOT to have benign growth of the prostate with increasing age. Prevalence.

Male Lower Urinary Tract Symptoms: Management in primary care and beyond. Daniel Cohen PhD FRCS(Urol) Consultant Urological Surgeon

As man draws near the common goal Can anything be sadder Than he who, master of his soul Is servant to his bladder LUTS 2. Prevalence of BPH LUTS 5

URINARY INCONTINENCE. Urology Division, Surgery Department Medical Faculty, University of Sumatera Utara

Various Types. Ralph Boling, DO, FACOG

Priorities Forum Statement GUIDANCE

MANAGING BENIGN PROSTATIC HYPERTROPHY IN PRIMARY CARE DR GEORGE G MATHEW CONSULTANT FAMILY PHYSICIAN FELLOW IN SEXUAL & REPRODUCTIVE HEALTH

Management of LUTS. Simon Woodhams February 2012

Urinary Incontinence. Lora Keeling and Byron Neale

LUTS A plea for a holistic approach. HUBERT GALLAGHER, MCh; FRCSI, FRCSI(Urol) Head of Urology Beacon Hospital

Lower Urinary Tract Symptoms (LUTS) and Nurse-Led Clinics. Sean Diver Urology Advanced Nurse Practitioner candidate Letterkenny University Hospital

Bladder dysfunction in ALD and AMN

Voiding Dysfunction Block lecture, 5 th year student. Choosak Pripatnanont, Department of Surgery, PSU.

Disclosures. Geriatric Incontinence and Voiding Dysfunction. Agenda. Agenda. UI: a Geriatric Syndrome. Geriatric Syndromes 9/7/2018.

Urogynecology in EDS. Joan L. Blomquist, MD Greater Baltimore Medical Center August 2018

Mr. GIT KAH ANN. Pakar Klinikal Urologi Hospital Kuala Lumpur.

Management of Female Stress Incontinence

Primary Care management of Overactive Bladder (OAB)

Content. Terminology Anatomy Aetiology Presentation Classification Management

Management of OAB. Lynsey McHugh. Consultant Urological Surgeon. Lancashire Teaching Hospitals

All about the Prostate

Objectives. Prevalence of Urinary Incontinence URINARY INCONTINENCE: EVALUATION AND CURRENT TREATMENT OPTIONS

John Laughlin 4 th year Cardiff University Medical Student

Diagnosis and Mangement of Nocturia in Adults

Urogynaecology. Colm McAlinden

Patient Information. Basic Information on Overactive Bladder Symptoms. pubic bone. urethra. scrotum. bladder. vaginal canal

Overactive bladder syndrome (OAB)

Management of male LUTS in general practice

Urinary Incontinence. Vibhash Mishra Consultant Urological Surgeon Royal Free Hospital

Diagnostic approach to LUTS in men. Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center

EAU GUIDELINES ON URINARY INCONTINENCE

AUCKLAND REGIONAL UROLOGY GUIDELINES AND REFERRAL RECOMMENDATIONS

The management of lower urinary tract symptoms in men

Newcastle upon Tyne, Gateshead and Northumbria Urology guidelines

LUTS after TURP: How come and how to manage? Matthias Oelke

NEUROGENIC BLADDER. Dr Harriet Grubb Dr Alison Seymour Dr Alexander Joseph

EAU GUIDELINES ON URINARY INCONTINENCE

Overview. Urology Dine and Learn: Erectile Dysfunction & Benign Prostatic Hyperplasia. Iain McAuley September 15, 2014

NON-Neurogenic Chronic Urinary Retention AUA White Paper

Overactive Bladder: Diagnosis and Approaches to Treatment

Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline.

Overactive bladder can result from one or more of the following causes:

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

Prolapse and Urogynae Incontinence. Lucy Tiffin and Hannah Wheldon-Holmes

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Centre for Clinical Practice Surveillance Programme

Telford and Wrekin Clinical Commissioning Group

Overactive bladder. Information for patients from Urogynaecology

INCONTINENCE. Continence and Pelvic Floor Rehabilitation TYPES OF INCONTINENCE STRESS INCONTINENCE STRESS INCONTINENCE STRESS INCONTINENCE 11/08/2015

Management of LUTS after TURP and MIT

SELF CARE IN URINARY INCONTINENCE

Urology Case Study Workbook - Questions

21/03/2016. The urogynaecologist approach. Urinary continence management in women: a multidisciplinary approach. Dr Anna Rosamillia

URGE MOTOR INCONTINENCE

25-Feb-16 MANAGEMENT OF URINARY INCONTINENCE IN WOMEN.

Victoria Sharp, MD, MBA, FAAFP. Clinical Professor of Urology and Family Medicine

Dr Jonathan Evans Paediatric Nephrologist

Urinary Incontinence for the Primary Care Provider

CONTINENCE MODULE 1 MIMIMUM STANDARDS FOR THE SPECIALIST ASSESSMENT & CONSERVATIVE MANAGEMENT OF FEMALE LOWER URINARY TRACT SYMPTOMS

NICE guideline Published: 2 April 2019 nice.org.uk/guidance/ng123

Geriatric Urinary Incontinence

NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE SCOPE. Urinary incontinence: the management of urinary incontinence in women

Incontinence in neurological disease

Management, Evaluation, and Treatment of Overactive Bladder and Urinary Incontinence

GUIDELINES ON URINARY INCONTINENCE

Pelvic Floor Therapy for the Neurologic Client Carina Siracusa, PT, DPT, WCS

The Management of Female Urinary Incontinence. Part 1: Aetiology and Investigations

PROSTATIC ARTERY EMBOLISATION (PAE) FOR BENIGN PROSTATIC HYPERPLASIA. A Minimally Invasive Innovative Treatment

Benign Prostatic Hyperplasia. Jay Lee, MD, FRCSC Clinical Associate Professor University of Calgary

Stress Incontinence. Susannah Elvy Urogynaecology CNS

The Royal Marsden. Prostate case study. Presented by Mr Alan Thompson Consultant Urological Surgeon

Overactive Bladder in Clinical Practice

GUIDELINES ON NON-NEUROGENIC MALE LUTS INCLUDING BENIGN PROSTATIC OBSTRUCTION

Prostate Disease. Chad Baxter, MD

Diane K. Newman DNP, ANP-BC, PCB-PMD, FAAN

Ambulatory Emergency Care Pathways. Acute Painful Bladder Outflow Obstruction

NICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic.

GUIDELINES ON NON-NEUROGENIC MALE LUTS INCLUDING BENIGN PROSTATIC OBSTRUCTION (BPO)

Information for Patients. Overactive bladder syndrome (OAB) English

Lower urinary tract symptoms

Managing Female Urinary Incontinence Within Primary Care

Managing lower urinary tract symptoms in men

Incontinence: The silent scourge of the young and old. The International Continence Society has. In this article:

EAU GUIDELINES ON NON- NEUROGENIC MALE LUTS INCLUDING BENIGN PROSTATIC OBSTRUCTION

Disease Management. Incontinence Care. Chan Sau Kuen Continence Nurse Consultant United Christian Hospital 14/11/09

R. Matthew Smith M.D. Stacy Pohlman, ARNP Jessica Gengler, PT, DPT Mercy Urology

LUTS in the modern era. Dr Jon Rees Tyntesfield Medical Group

Diagnosis and Treatment of Urinary Incontinence. Urinary Incontinence

Urinary incontinence in women & men

Urinary dysfunction assessment tool (care home)

Urinary tract disorders

The Management of Overactive Bladder Syndrome with Antimuscarinic Drugs

Benign Prostatic Hyperplasia (BPH):

Physiology & Neurophysiology of lower U.T.

Dr. Aso Urinary Symptoms

Geriatric Giants Lecture Series: Urinary incontinence

Transcription:

LUTS & Cancer pathway Mr Francis Thomas Urology Consultant DRI &BDGH

Topics Male and female LUTS Urinary retention Post void Residual urine Referral pathway LUTS Raised PSA Hematuria Services in community

Causes of LUTS in men BPE Life style habits Detrusor muscle weakness or overactivity, Prostate inflammation, UTI Prostate cancer Neurological diseases Medical causes Medications Renal BOO Pituitary LUTS Cardiac CNS BPE

Initial assessment History Predominant symptoms Life style General medical history Drug history Physical examination Abdomen DRE Genitalia IPSS score Urine dipstick

Initial assessment PSA- Abnormal prostate Patient concerns Serum creatinine- Suspect renal impairment Palpable bladder Nocturnal eneuresis Recurrent UTI H/o Renal stones USS KUB Suspecting renal failure

Conservative Management Reassurance and further information Life style interventions- mainly for storage symptoms Fluid balance Decrease tea/coffee/ alcohol/fizzy drinks Decrease night time drinks Bladder training Treat bowel constipation Reduce weight

Drug treatment Alpha blocker for moderate to severe LUTS ( eg: Tamsulosin, Alfuzosin) Anticholinergics for OAB (Solifenacin, Tolteridine etc) 5 alpha reductase (Finasteride, Dutasteride) Prostate >30gm PSA >1.4ng/ml High risk for progression Combination therapy (alpha blocker+5 alpha reductase) Bothersome moderate to severe LUTS Prostate >30gm PSA >1.4ng/ml High risk for progression Alpha blocker+ Anticholinergic Persistent storage symptoms after treatment with alpha blocker alone

% Improvement in max Flow Improvement in Flow Q max Prazosin, Alfuzosin, Tamsulosin, Terazosin 40 35 30 25 20 15 10 5 0 Buzelin 93 Buzelin 97 Lee 97 Na 98

Effect of finasteride on prostate volume Effect&of&finasteride&on&prostate&volume 20% 32% N"Engl"J"Med"

Mainly Voiding symptoms Mainly storage symptoms Voiding +storage symptoms Voiding symptoms +Erectile dysfunction Alpha blocker Life style advise Alpha blocker + anticholinergic+/- life style advise Alpha blocker + PDE5 inhibitor Large prostate PSA>1.4 Symptoms not improved Anticholinergics Alpha blocker + 5 alpha reductase

SCENARIOS 60 YEAR OLD MAN presenting with Slow stream, hesistancy, frequency Urinalysis negative PSA- 0.4 PR- moderate size BPE

55 year old man with urgency, frequency, hesitancy Urine positive for Nonvisible hematuria PR- moderate size bpe

Review after 4-6 weeks Continue active monitoring (reassurance and lifestyle modifications) Active intervention Drug therapy Referral to specialist

Referral Bothersome LUTS Not responded to drug treatment Complicated LUTS UTI Retention Renal impairment Lower urinary tract dysfunction Suspected malignancy Hematuria Abnormal prostate Raised PSA

Nocturia Waking to pass urine during the main sleep period Causes Nocturnal polyuria (It is defined as passing more than one third of your 24-hour urine output at night ) BPE UTI Medications Medical causes- cardiac failure Sleep apnoea-sleep disturbances

Nocturia-assessment History- Identify causative factors Lifestyle habits Fluid intake Assess with Frequency volume chart Urinalysis

Nocturia Lifestyle modifications Less fluid intake after 6 pm Reduce salt and sugar in diet Simple evening leg elevation or compression stockings can redistribute third space fluid Continuous positive airway pressure (CPAP) Alpha blockers- for BPE Anticholinergics-minimal effect Afternoon diuretics Desmopressin- oral or nasal spray ( monitor Sodium)

Retention of urine Acute retention < 1000 ml urine Painful Acute on chronic retention >1litre urine Painful Chronic retention RV>1 L, Palpable bladder painless High pressure chronic retention Painful or painless Renal failure, Hydroureteronephrosis (on USS KUB) Investigations +assessment Prostate examination Check U&E USS KUB if renal failure Management Acute retention Catheterise- GP practice/rdash/hospital Alpha blocker before TWOC (after 48hrs) C/C retention with symptoms ISC catheter Surgery C/C retention without symptoms (not catheterised) Active surveillance- monitor PV RV USS kidneys Serum creatinine

Retention of urine High pressure chronic retention Renal failure, Hydroureteronephrosis RX Catheterise Admit in hospital for monitoring LTC/Surgery

Effect of medical therapy on the development of AUR Effect&of&medical&therapy&on&the& development&of&aur Incidence:of:AUR/100:patient: years 6 5 4 3 2 1 0 36/1503 7/134 4/252 *14/1513 1/172 3/237 *1/126 2/179 0/249 4/811 placebo finasteride alpha7blocker PLESS ALF ALFIN PREDICT TAM Michel&MC.&Drugs&Today&2000J36(Suppl.F):11P13

75 year old man presents with difficulty passing urine through out night. Fit and well O/E palpable bladder

AUR/TWOC Community pathway -RDASH AUR in community DRI Urology Department Patient presenting with AUR in communityrefer to unplanned care services for catheterisation and then seen in RDASH clinic for assessment /TWOC and further referral to Urology Patients discharged from hospitals with catheter referred to RDASH clinic for TWOC or for further catheter care Patients given clear advise and support with catheter passport and contact details of RDASH clinic TWOC from community RDASH/ UNPLANNED CARE ISC/CATHETER PROBLEMS TWOC from hospital

Post void scans /USS KUB Post void residuals No minimal or maximum values Take into consideration Symptoms UTI Renal function Treatment depends on whether symptomatic or not Renal function

Surgery- mainly storage symptoms Failed conservative and drug treatment Urodynamic studies to assess bladder Botulinum toxin injection Sacral nerve neuromodulation Cystoplasty Willing and able to self catheterize Detrusor overactivity Small capacity bladder Artificial sphincter- stress UI Urinary diversion Failed cystoplasty Failed sacral nerve stimulation

Surgery- voiding symptoms -Severe voiding symptoms -Failed drug and conservative treatment TURP Monopolar/bipolar Green light Prostate embolisation HoLEP Uro-lift Aqua ablation Open prostatectomy->80-100 gm prostate

Female LUTS Mr Francis Thomas Consultant Urologist DRI &BDGH

Definitions Urgency -a sudden compelling desire to urinate that is difficult to delay Urgency UI is involuntary urine leakage accompanied or immediately preceded by urgency Stress UI is involuntary urine leakage on effort or exertion or on sneezing or coughing. Mixed UI is involuntary urine leakage associated with both urgency and exertion, effort, sneezing or coughing. Overactive bladder (OAB) is defined as urgency that occurs with or without urgency UI and usually with frequency and nocturia. OAB that occurs with incontinence is known as OAB wet OAB that occurs without incontinence is known as 'OAB dry

History Duration Type of incontinence Triggering factors- uti, stress Obstructive symptoms Pads usage numbers, size, wetness Lifestyle factors-caffeine, smoking, alcohol Menstural/obstetric Bowel habits Previous pelvic surgery/radiotherapy Drugs Medical problems diabetes etc

Assessment Frequency volume chart Minimum of 3 days to include rest days and working days Fluid dairy Urinalysis Post void residuals Pelvic and speculum examination Cough test USS pelvis

Specialist opinion Haematuria Recurrent UTI Persisting bladder or urethral pain Pelvic mass/palpable bladder Urogenital fistula Previous continence surgery Fecal incontinence Neurological disease Previous Pelvic cancer Previous pelvic radiotherapy

Treatment Categorise the symptoms and diagnose the type of incontinence SUI,UI,MIXED OR OAB Treat the predisposing and precipitating factors UTI, Constipation, Loose weight (BMI>30) Lifestyle advice Reduce caffeine/fizzydrinks/smoking Fluid intake 1.5-2litres Bladder training exercises Pelvic floor exercises If mixed incontinence start treating the predominant symptom SUI with OAB Treat OAB symptoms prior to treatment of SUI Prolapse that is symptomatic and is visible and or below the introitus should be treated

Treatment-Conservative measures BLADDER TRAINING -6 weeks-3 months There are many different regimes, but they all involve suppressing the feelings of urinary urgency. Require a few months training to reach its full potential. Timed voiding Pelvic floor muscle training(pfmt) Assess pelvic muscle tone Supervised PFMT- 3months 8 contractions each held for 8 seconds three times a day RDASH clinic and physiotherapy department- offers bladder training and PFMT advice

Treatment PADS/CATHETERS/URINALS -Use them only as Coping strategy pending assessment and treatment An adjunct to ongoing treatment When all treatment options have been explored and failed

Medications Start with one with low acquisition cost Most of anticholinergics have same side effect profile Oxybutynin-(not in elderly) Tolteridine - Darifenacin- Solifenacin- Trospium chloride Fesoteridine Mirabegron- beta 3 agonist Mirabegron +anticholinergic Topical oestrogens for vaginal atrophy-6 weeks to 3months OAB DRUGS Counsel about success and associated common side effects Some side effects indicate that the treatment is starting to have an effect May take up to 4 weeks for medicines to start working Need to continue with bladder training /PFMT along with OAB drugs 4 week review and then 6month review Try atleast two drugs before referral to specialist centres

Referral- &secondary care If OAB symptoms, SUI/mixed incontinence not responding to bladder training, PFMT and OAB drugs OAB MDT Urodynamics Intravesical Botulinum toxin Posterior tibial nerve stimulation Sacral neuro modulation Augmentation cystoplasty Urinary diversion-ileal conduit SUI MDT Urodynamics Rectus fascial slings Colposuspension Urethral bulking agents Artificial sphincters Urinary diversion

Hospital pathway Women with bladder symptoms Community pathway- RDASH Urinalysis GP Urinalysis Clinical examination & medications Urology clinic Flow rate & bladder scan Pelvic floor exercise RDASH clinic Flow rate & bladder scan Fluid and dietary advise Clinical examination & medications Fluid and dietary advise Referred for Pelvic floor exercises Referred to Gynaecologist if prolapse etc-- Referred to Urology/Gynaecology MDT as appropriate Discharged if symptoms resolved Clinic revisit 6-8 weeks

Clinical scenarios 40 year old lady presenting with frequency,urgency, incontinence for 3 months. Otherwise fit and well.

40 year old lady presenting with frequency,urgency, incontinence for 3 months. Otherwise fit and well. Already on medications (anticholinergic) for 2 months but symptoms not better.

65 year old lady with frequency, urgency and hesitancy, otherwise fit and well. O/E microscopic hematuria, vaginal atrophy.

Cancer 2 WW Pathways

Hematuria referral 2 ww referral >45 yrs of age hematuria without UTI Non visible hematuria (NVH) >60 yrs and have either dysuria or raised WBC count Non urgent referral Visible hematuria <45 yrs of age Non visible hematuria <60 yrs Recurrent UTI NVH with proteinuria / renal failure Refer renal physician

3 CLINIC VISITS Current pathway Abnormal PSA One stop PSA clinic Abnormal PSA Seen in clinic- 2WW MRI PROSTATE One stop PSA clinic 2WW MRI done and reported same day PROSTATE BIOPSY- same day MRI MDT PROSTATE BIOPSY MDT ONCOLOGY ONCOLOGY MDT CLINIC CLINIC

South Yorkshire, Bassetlaw and North Derbyshire Cancer Alliance Urology Fast Track Referral 2 Week Wait

Prostate Cancer All Patients should have PSA and U&E/eGFR blood tests, urine dipstick and Digital Rectal Examination (DRE) 1. Asymptomatic patient requesting PSA test Require two blood tests, at least 4 weeks apart Informed consent: e.g. Prostate Cancer Risk Management Programme (PCRMP) leaflet Refer as 2ww if: Both PSA >3.0 (for all ages) (For raised PSA in men with significant co-morbidities, performance status >3 or life expectancy <10 years, consider discussion with patient/family/carers and/or a specialist before urgent referral.) https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/509191/patient_info_sheet.pdf

Prostate Cancer All Patients should have PSA and U&E/eGFR blood tests, urine dipstick and Digital Rectal Examination (DRE) 2. Symptomatic patient: Prostatic symptoms/luts Please Wait atleast 6 weeks following treated UTI before undertaking PSA test. Refer if: Abnormal DRE Or Both PSA >3.0 (Obtain two PSA tests, at least 4 weeks apart) (For raised PSA in men with significant co-morbidities, performance status >3 or life expectancy <10 years, consider discussion with patient/family/carers and/or a specialist before urgent referral.) Informed consent: e.g. (PCRMP) leaflet provided

Prostate Cancer All Patients should have PSA and U&E/eGFR blood tests, urine dipstick and Digital Rectal Examination (DRE) 3. Symptomatic patient: Suspected distant metastases Refer: If abnormal DRE Or a single PSA >20 In this group of patients if PSA result is between 10-20 suggest repeat and review in 4 weeks with second PSA test. If repeat PSA level <10 Constitutional symptoms are unlikely to be directly due to prostate cancer but consider criteria above.

Prostate Cancer All Patients should have PSA and U&E/eGFR blood tests, urine dipstick and Digital Rectal Examination (DRE) 4. Prostate feels malignant (Firm, hard, nodular or craggy) on (DRE) One PSA is sufficient, Any PSA value